Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties
The present research aims to study the effects of guluronic acid (G2013) on gene expression levels of the T-bet, GATA3, RORγt, AHR, and FOXP3 transcription factors and on gene expression of their related cytokines following oral administration of this drug in ankylosing spondylitis (AS) patients. In...
Gespeichert in:
| Veröffentlicht in: | Immunologic research 2019-02, Vol.67 (1), p.108-115 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 115 |
|---|---|
| container_issue | 1 |
| container_start_page | 108 |
| container_title | Immunologic research |
| container_volume | 67 |
| creator | Mortazavi-Jahromi, Seyed Shahabeddin Nazeri, Sepideh Jafarnezhad-Ansariha, Fahimeh Oraei, Mona Mirshafiey, Abbas |
| description | The present research aims to study the effects of guluronic acid (G2013) on gene expression levels of the T-bet, GATA3, RORγt, AHR, and FOXP3 transcription factors and on gene expression of their related cytokines following oral administration of this drug in ankylosing spondylitis (AS) patients. In this trial (clinical trial identifier: IRCT2016091813739N4), 14 AS patients and 12 age- and sex-matched healthy individuals were enrolled. The level of transcription factors’ gene expression and expression of their related cytokines were measured by quantitative real-time PCR, before and 3 months after G2013 therapy. Our data indicated that the gene expression levels of the T-bet and IFN-γ were not significantly reduced during 12 weeks of treatment with G2013 (
p
> 0.05). The findings showed that the gene expression levels of the GATA3 and IL-4 increased significantly during 12 weeks of treatment with G2013 (
p
|
| doi_str_mv | 10.1007/s12026-018-9042-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2138041490</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2137396926</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-16a87d5fb0a496ab6f61a513365dfe46e1395efa1f4fa2f7fbd72abcd39b4efe3</originalsourceid><addsrcrecordid>eNp1kU-L1TAUxYMozpvRD-BGAm5mwGr-53X5GHUcGHShgruStskzY5p0clse70v5GU3tqCC4yYXc37nnwEHoGSWvKCH6NVBGmKoI3VY1EaziD9CGSllXREv5EG0Ik7piWn89QacAt4RQJQR_jE44EVpsOd-gHzsACzDYOOHksB-GOaaQ9r4zAY85OR8s9hGb-P0YEvi4xzCm2B-Dnzzg0Uy-SAG7FEI6LGuDu-DjL_2UfXkPfvqG93OYcyrf2HS-x-dXjFB-8RIbKIJoD_jDp931m5VdQwypn4OZUj4uOUabixM8QY-cCWCf3s8z9OXd28-X76ubj1fXl7ubquOaTRVVZqt76VpiRK1Mq5yiRlLOleydFcpSXkvrDHXCGea0a3vNTNv1vG6FdZafofP1brG-my1MzeChsyGYaNMMDaN8SwQVNSnoi3_Q2zTnWNItlOa1qpkqFF2pLieAbF0zZj-YfGwoaZYym7XMppTZLGU2vGie31-e28H2fxS_2ysAWwEoq7i3-a_1_6_-BPeerc8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2137396926</pqid></control><display><type>article</type><title>Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Mortazavi-Jahromi, Seyed Shahabeddin ; Nazeri, Sepideh ; Jafarnezhad-Ansariha, Fahimeh ; Oraei, Mona ; Mirshafiey, Abbas</creator><creatorcontrib>Mortazavi-Jahromi, Seyed Shahabeddin ; Nazeri, Sepideh ; Jafarnezhad-Ansariha, Fahimeh ; Oraei, Mona ; Mirshafiey, Abbas</creatorcontrib><description>The present research aims to study the effects of guluronic acid (G2013) on gene expression levels of the T-bet, GATA3, RORγt, AHR, and FOXP3 transcription factors and on gene expression of their related cytokines following oral administration of this drug in ankylosing spondylitis (AS) patients. In this trial (clinical trial identifier: IRCT2016091813739N4), 14 AS patients and 12 age- and sex-matched healthy individuals were enrolled. The level of transcription factors’ gene expression and expression of their related cytokines were measured by quantitative real-time PCR, before and 3 months after G2013 therapy. Our data indicated that the gene expression levels of the T-bet and IFN-γ were not significantly reduced during 12 weeks of treatment with G2013 (
p
> 0.05). The findings showed that the gene expression levels of the GATA3 and IL-4 increased significantly during 12 weeks of treatment with G2013 (
p
< 0.05). In addition, gene expression levels of the RORγt, IL-17, AHR, and IL-22 decreased significantly during the 12-week treatment with G2013 (
p
< 0.05). Moreover, the gene expression level of the FOXP3 increased significantly during 12 weeks of treatment with G2013, but the gene expression level of IL-10 did not increase significantly (
p
< 0.05,
p
> 0.05, respectively). The present study showed that oral intake of G2013 was able to modify the severity of articular and inflammatory symptoms of AS through reducing the gene expression levels of the RORγt, IL-17, AHR, and IL-22 and increasing the gene expression levels of the GATA3, IL-4, and FOXP3.</description><identifier>ISSN: 0257-277X</identifier><identifier>EISSN: 1559-0755</identifier><identifier>DOI: 10.1007/s12026-018-9042-3</identifier><identifier>PMID: 30474833</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adolescent ; Adult ; Allergology ; Ankylosing spondylitis ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Arthritis ; Biomedical and Life Sciences ; Biomedicine ; Clinical trials ; Cytokines ; Forkhead Transcription Factors - genetics ; Forkhead Transcription Factors - metabolism ; Foxp3 protein ; GATA-3 protein ; GATA3 Transcription Factor - genetics ; GATA3 Transcription Factor - metabolism ; Gene expression ; Gene Expression Regulation ; Hexuronic Acids - therapeutic use ; Humans ; Immunology ; Immunomodulation ; Inflammation ; Interleukin 10 ; Interleukin 17 ; Interleukin 22 ; Interleukin 4 ; Interleukin-4 - genetics ; Interleukin-4 - metabolism ; Internal Medicine ; Male ; Medicine/Public Health ; Middle Aged ; Nonsteroidal anti-inflammatory drugs ; Oral administration ; Original Article ; Patients ; Spondylitis, Ankylosing - drug therapy ; Transcription factors ; Treatment Outcome ; Young Adult ; γ-Interferon</subject><ispartof>Immunologic research, 2019-02, Vol.67 (1), p.108-115</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>Immunologic Research is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-16a87d5fb0a496ab6f61a513365dfe46e1395efa1f4fa2f7fbd72abcd39b4efe3</citedby><cites>FETCH-LOGICAL-c372t-16a87d5fb0a496ab6f61a513365dfe46e1395efa1f4fa2f7fbd72abcd39b4efe3</cites><orcidid>0000-0003-1996-2747</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12026-018-9042-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12026-018-9042-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30474833$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mortazavi-Jahromi, Seyed Shahabeddin</creatorcontrib><creatorcontrib>Nazeri, Sepideh</creatorcontrib><creatorcontrib>Jafarnezhad-Ansariha, Fahimeh</creatorcontrib><creatorcontrib>Oraei, Mona</creatorcontrib><creatorcontrib>Mirshafiey, Abbas</creatorcontrib><title>Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties</title><title>Immunologic research</title><addtitle>Immunol Res</addtitle><addtitle>Immunol Res</addtitle><description>The present research aims to study the effects of guluronic acid (G2013) on gene expression levels of the T-bet, GATA3, RORγt, AHR, and FOXP3 transcription factors and on gene expression of their related cytokines following oral administration of this drug in ankylosing spondylitis (AS) patients. In this trial (clinical trial identifier: IRCT2016091813739N4), 14 AS patients and 12 age- and sex-matched healthy individuals were enrolled. The level of transcription factors’ gene expression and expression of their related cytokines were measured by quantitative real-time PCR, before and 3 months after G2013 therapy. Our data indicated that the gene expression levels of the T-bet and IFN-γ were not significantly reduced during 12 weeks of treatment with G2013 (
p
> 0.05). The findings showed that the gene expression levels of the GATA3 and IL-4 increased significantly during 12 weeks of treatment with G2013 (
p
< 0.05). In addition, gene expression levels of the RORγt, IL-17, AHR, and IL-22 decreased significantly during the 12-week treatment with G2013 (
p
< 0.05). Moreover, the gene expression level of the FOXP3 increased significantly during 12 weeks of treatment with G2013, but the gene expression level of IL-10 did not increase significantly (
p
< 0.05,
p
> 0.05, respectively). The present study showed that oral intake of G2013 was able to modify the severity of articular and inflammatory symptoms of AS through reducing the gene expression levels of the RORγt, IL-17, AHR, and IL-22 and increasing the gene expression levels of the GATA3, IL-4, and FOXP3.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Allergology</subject><subject>Ankylosing spondylitis</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Arthritis</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Forkhead Transcription Factors - genetics</subject><subject>Forkhead Transcription Factors - metabolism</subject><subject>Foxp3 protein</subject><subject>GATA-3 protein</subject><subject>GATA3 Transcription Factor - genetics</subject><subject>GATA3 Transcription Factor - metabolism</subject><subject>Gene expression</subject><subject>Gene Expression Regulation</subject><subject>Hexuronic Acids - therapeutic use</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunomodulation</subject><subject>Inflammation</subject><subject>Interleukin 10</subject><subject>Interleukin 17</subject><subject>Interleukin 22</subject><subject>Interleukin 4</subject><subject>Interleukin-4 - genetics</subject><subject>Interleukin-4 - metabolism</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine/Public Health</subject><subject>Middle Aged</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Oral administration</subject><subject>Original Article</subject><subject>Patients</subject><subject>Spondylitis, Ankylosing - drug therapy</subject><subject>Transcription factors</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><subject>γ-Interferon</subject><issn>0257-277X</issn><issn>1559-0755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kU-L1TAUxYMozpvRD-BGAm5mwGr-53X5GHUcGHShgruStskzY5p0clse70v5GU3tqCC4yYXc37nnwEHoGSWvKCH6NVBGmKoI3VY1EaziD9CGSllXREv5EG0Ik7piWn89QacAt4RQJQR_jE44EVpsOd-gHzsACzDYOOHksB-GOaaQ9r4zAY85OR8s9hGb-P0YEvi4xzCm2B-Dnzzg0Uy-SAG7FEI6LGuDu-DjL_2UfXkPfvqG93OYcyrf2HS-x-dXjFB-8RIbKIJoD_jDp931m5VdQwypn4OZUj4uOUabixM8QY-cCWCf3s8z9OXd28-X76ubj1fXl7ubquOaTRVVZqt76VpiRK1Mq5yiRlLOleydFcpSXkvrDHXCGea0a3vNTNv1vG6FdZafofP1brG-my1MzeChsyGYaNMMDaN8SwQVNSnoi3_Q2zTnWNItlOa1qpkqFF2pLieAbF0zZj-YfGwoaZYym7XMppTZLGU2vGie31-e28H2fxS_2ysAWwEoq7i3-a_1_6_-BPeerc8</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Mortazavi-Jahromi, Seyed Shahabeddin</creator><creator>Nazeri, Sepideh</creator><creator>Jafarnezhad-Ansariha, Fahimeh</creator><creator>Oraei, Mona</creator><creator>Mirshafiey, Abbas</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1996-2747</orcidid></search><sort><creationdate>20190201</creationdate><title>Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties</title><author>Mortazavi-Jahromi, Seyed Shahabeddin ; Nazeri, Sepideh ; Jafarnezhad-Ansariha, Fahimeh ; Oraei, Mona ; Mirshafiey, Abbas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-16a87d5fb0a496ab6f61a513365dfe46e1395efa1f4fa2f7fbd72abcd39b4efe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Allergology</topic><topic>Ankylosing spondylitis</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Arthritis</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Forkhead Transcription Factors - genetics</topic><topic>Forkhead Transcription Factors - metabolism</topic><topic>Foxp3 protein</topic><topic>GATA-3 protein</topic><topic>GATA3 Transcription Factor - genetics</topic><topic>GATA3 Transcription Factor - metabolism</topic><topic>Gene expression</topic><topic>Gene Expression Regulation</topic><topic>Hexuronic Acids - therapeutic use</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunomodulation</topic><topic>Inflammation</topic><topic>Interleukin 10</topic><topic>Interleukin 17</topic><topic>Interleukin 22</topic><topic>Interleukin 4</topic><topic>Interleukin-4 - genetics</topic><topic>Interleukin-4 - metabolism</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine/Public Health</topic><topic>Middle Aged</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Oral administration</topic><topic>Original Article</topic><topic>Patients</topic><topic>Spondylitis, Ankylosing - drug therapy</topic><topic>Transcription factors</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mortazavi-Jahromi, Seyed Shahabeddin</creatorcontrib><creatorcontrib>Nazeri, Sepideh</creatorcontrib><creatorcontrib>Jafarnezhad-Ansariha, Fahimeh</creatorcontrib><creatorcontrib>Oraei, Mona</creatorcontrib><creatorcontrib>Mirshafiey, Abbas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Immunologic research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mortazavi-Jahromi, Seyed Shahabeddin</au><au>Nazeri, Sepideh</au><au>Jafarnezhad-Ansariha, Fahimeh</au><au>Oraei, Mona</au><au>Mirshafiey, Abbas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties</atitle><jtitle>Immunologic research</jtitle><stitle>Immunol Res</stitle><addtitle>Immunol Res</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>67</volume><issue>1</issue><spage>108</spage><epage>115</epage><pages>108-115</pages><issn>0257-277X</issn><eissn>1559-0755</eissn><abstract>The present research aims to study the effects of guluronic acid (G2013) on gene expression levels of the T-bet, GATA3, RORγt, AHR, and FOXP3 transcription factors and on gene expression of their related cytokines following oral administration of this drug in ankylosing spondylitis (AS) patients. In this trial (clinical trial identifier: IRCT2016091813739N4), 14 AS patients and 12 age- and sex-matched healthy individuals were enrolled. The level of transcription factors’ gene expression and expression of their related cytokines were measured by quantitative real-time PCR, before and 3 months after G2013 therapy. Our data indicated that the gene expression levels of the T-bet and IFN-γ were not significantly reduced during 12 weeks of treatment with G2013 (
p
> 0.05). The findings showed that the gene expression levels of the GATA3 and IL-4 increased significantly during 12 weeks of treatment with G2013 (
p
< 0.05). In addition, gene expression levels of the RORγt, IL-17, AHR, and IL-22 decreased significantly during the 12-week treatment with G2013 (
p
< 0.05). Moreover, the gene expression level of the FOXP3 increased significantly during 12 weeks of treatment with G2013, but the gene expression level of IL-10 did not increase significantly (
p
< 0.05,
p
> 0.05, respectively). The present study showed that oral intake of G2013 was able to modify the severity of articular and inflammatory symptoms of AS through reducing the gene expression levels of the RORγt, IL-17, AHR, and IL-22 and increasing the gene expression levels of the GATA3, IL-4, and FOXP3.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>30474833</pmid><doi>10.1007/s12026-018-9042-3</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-1996-2747</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0257-277X |
| ispartof | Immunologic research, 2019-02, Vol.67 (1), p.108-115 |
| issn | 0257-277X 1559-0755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2138041490 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adolescent Adult Allergology Ankylosing spondylitis Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Arthritis Biomedical and Life Sciences Biomedicine Clinical trials Cytokines Forkhead Transcription Factors - genetics Forkhead Transcription Factors - metabolism Foxp3 protein GATA-3 protein GATA3 Transcription Factor - genetics GATA3 Transcription Factor - metabolism Gene expression Gene Expression Regulation Hexuronic Acids - therapeutic use Humans Immunology Immunomodulation Inflammation Interleukin 10 Interleukin 17 Interleukin 22 Interleukin 4 Interleukin-4 - genetics Interleukin-4 - metabolism Internal Medicine Male Medicine/Public Health Middle Aged Nonsteroidal anti-inflammatory drugs Oral administration Original Article Patients Spondylitis, Ankylosing - drug therapy Transcription factors Treatment Outcome Young Adult γ-Interferon |
| title | Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A05%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20immunological%20profile%20in%20ankylosing%20spondylitis%20patients%20following%20a%20clinical%20trial%20with%20guluronic%20acid%20(G2013),%20as%20a%20new%20NSAID%20with%20immunomodulatory%20properties&rft.jtitle=Immunologic%20research&rft.au=Mortazavi-Jahromi,%20Seyed%20Shahabeddin&rft.date=2019-02-01&rft.volume=67&rft.issue=1&rft.spage=108&rft.epage=115&rft.pages=108-115&rft.issn=0257-277X&rft.eissn=1559-0755&rft_id=info:doi/10.1007/s12026-018-9042-3&rft_dat=%3Cproquest_cross%3E2137396926%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2137396926&rft_id=info:pmid/30474833&rfr_iscdi=true |